NANOBIONÁLISIS
NBA
Hospital Universitario de Canarias
San Cristóbal de La Laguna, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (8)
2024
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
-
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)
Leukemia and Lymphoma, Vol. 63, Núm. 14, pp. 3438-3447
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345